PMID- 15034863
OWN - NLM
STAT- MEDLINE
DCOM- 20040525
LR  - 20191210
IS  - 1045-2257 (Print)
IS  - 1045-2257 (Linking)
VI  - 40
IP  - 1
DP  - 2004 May
TI  - Interphase fluorescence in situ hybridization for detection of 8q24/MYC 
      breakpoints on routine histologic sections: validation in Burkitt lymphomas from 
      three geographic regions.
PG  - 10-8
AB  - A chromosomal translocation involving the MYC gene is characteristic of Burkitt 
      lymphoma (BL) and represents a molecular disease marker with diagnostic and 
      clinical implications. The detection of MYC breakpoints is hampered by technical 
      problems, including the distribution of the breakpoints over a very large genomic 
      region of approximately 1,000 kb. In this article, we report on the testing and 
      validation of a segregation fluorescence in situ hybridization (FISH) assay for 
      MYC breakpoints on a large series of BLs. A contig of overlapping genomic clones 
      was generated, and two probe sets flanking the MYC gene were selected. Both probe 
      sets were tested in an interphase FISH segregation assay on 8 B-cell lymphoma 
      cell lines and 32 lymphoma samples with proved 8q24/MYC abnormalities and 
      validated in 47 BLs from The Netherlands, Brazil, and Uganda. MYC translocation 
      breakpoints were identified in 98% of the tumors of the test series and in 89% of 
      the cases of the validation series. In 89% of all positive samples, the 
      breakpoints were located between 190 kb 5' and 50 kb 3' of MYC. Nine cases had 
      more distant breakpoints, and in one patient an insertion of MYC into the IGH 
      region was detected. In two of the three BLs lacking CD10 expression, no 
      breakpoint could be detected, suggesting that CD10 is a discriminative marker of 
      BL. We did not find consistent differences between BL and atypical BL in 
      incidence of an MYC breakpoint.
CI  - Copyright 2004 Wiley-Liss, Inc.
FAU - Haralambieva, Eugenia
AU  - Haralambieva E
AD  - Department of Pathology & Laboratory Medicine, University Hospital Groningen, 
      Groningen, The Netherlands.
FAU - Schuuring, Ed
AU  - Schuuring E
FAU - Rosati, Stefano
AU  - Rosati S
FAU - van Noesel, Carel
AU  - van Noesel C
FAU - Jansen, Patty
AU  - Jansen P
FAU - Appel, Inge
AU  - Appel I
FAU - Guikema, Jeroen
AU  - Guikema J
FAU - Wabinga, Henry
AU  - Wabinga H
FAU - Bleggi-Torres, Luiz Fernando
AU  - Bleggi-Torres LF
FAU - Lam, King
AU  - Lam K
FAU - van den Berg, Eva
AU  - van den Berg E
FAU - Mellink, Clemens
AU  - Mellink C
FAU - van Zelderen-Bhola, Shama
AU  - van Zelderen-Bhola S
FAU - Kluin, Philip
AU  - Kluin P
LA  - eng
PT  - Journal Article
PT  - Validation Study
PL  - United States
TA  - Genes Chromosomes Cancer
JT  - Genes, chromosomes & cancer
JID - 9007329
RN  - 0 (DNA Probes)
RN  - 0 (DNA, Neoplasm)
RN  - EC 3.2.2.- (DNA Glycosylases)
RN  - EC 3.2.2.- (mutY adenine glycosylase)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Burkitt Lymphoma/epidemiology/*genetics/pathology
MH  - Cell Line, Tumor
MH  - Child
MH  - Child, Preschool
MH  - Chromosome Breakage/*genetics
MH  - Chromosomes, Human, Pair 8/*genetics
MH  - DNA Glycosylases/*genetics
MH  - DNA Probes/genetics
MH  - DNA, Neoplasm/genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Interphase/genetics
MH  - Lymphoma, B-Cell/chemistry/metabolism
MH  - Middle Aged
EDAT- 2004/03/23 05:00
MHDA- 2004/05/27 05:00
CRDT- 2004/03/23 05:00
PHST- 2004/03/23 05:00 [pubmed]
PHST- 2004/05/27 05:00 [medline]
PHST- 2004/03/23 05:00 [entrez]
AID - 10.1002/gcc.20009 [doi]
PST - ppublish
SO  - Genes Chromosomes Cancer. 2004 May;40(1):10-8. doi: 10.1002/gcc.20009.